Diffuse Large B-Cell Lymphoma News

News

Post-ASCT Pembrolizumab Maintenance Associated With Elevated Circulating DCs for DLBCL

02/11/2022

Early features of post-ASCT immune reconstitution is associated with a persistent elevation of circulating DCs in patients with cHL and DLBCL.

Early features of post-ASCT...

02/11/2022

Oncology

News

Polatuzumab Vedotin Combo Shows Promising Activity in R/R DLBCL

02/04/2022

Polatuzumab vedotin has shown promising activity when combined with rituximab and bendamustine in patients with R/R DLBCL.

Polatuzumab vedotin has shown...

02/04/2022

Oncology

News

Comparing R-MiniCHOP With or Without Azacitidine in Patients With Lymphomas, Including DLBCL

01/10/2022

A randomized study of R-miniCHOP with or without oral azacitidine in patients with newly diagnosed DLBCL, grade 3B FL, transformed lymphoma, and high-grade B-cell lymphomas with MTC and BCL2 and/or BCL6 rearrangements, was presented at the...

A randomized study of R-miniCHOP...

01/10/2022

Oncology

News

Acalabrutinib Plus AZD9150 is Safe and Effective in Patients With R/R DLBCL

01/04/2022

Data of the combination of acalabrutinib and AZD9150 in patients with R/R DLBCL from a phase 1 study were presented at the 2021 ASH Annual Meeting.

Data of the combination of...

01/04/2022

Oncology

News

Phase 1b Trial Shows Safety of CD19-7x19 CAR-T Cells in Combination With Anti-PD-1 Antibody for R/R DLBCL

01/04/2022

Data of CD19-7x19 CAR-T cells plus anti-PD-1 antibody from a groundbreaking clinical trial were presented at the 2021 ASH Annual Meeting to highlight the safety and efficacy of this new strategy.

Data of CD19-7x19 CAR-T cells...

01/04/2022

Oncology

News

Extranodal Presentation is Not a Prognostic Marker in Limited Stage DLBCL

12/22/2021

Data analyses from the 3 sequential SWOG trials were presented at the 2021 ASH Annual Meeting to highlight extranodal presentation in limited stage DLBCL.

Data analyses from the 3...

12/22/2021

Oncology

News

Naratuximab Emtansine Plus Rituximab Shows Safety in Patients With DLBCL and Other B-NHLs

12/08/2021

A phase 2 study of naratuximab emtansine plus rituximab found it has promising safety and efficacy for patients with DLBCL and other B-NHLs; these data were presented at the 2021 Annual ASH Meeting.

A phase 2 study of naratuximab...

12/08/2021

Oncology

News

FDA Approves Rituximab Plus Chemo for Certain Pediatric Cancers

12/03/2021

On December 2, 2021, the FDA approved the combination of rituximab plus chemotherapy for previously untreated pediatric patients with advanced stage CD20+ DLBCL, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.

On December 2, 2021, the FDA...

12/03/2021

Oncology

News

Tafasitamab Associated With Meaningful, Well-Defined, Long-Term Outcomes in R/R DLBCL

12/02/2021

An updated analysis of the phase 2 L-MIND trial showed tafasitamab had meaningful OS and a well-defined safety profile in patients with R/R DLBCL.

An updated analysis of the phase...

12/02/2021

Oncology

News

Selinexor Associated With Increased OS in R/R DLBCL

12/02/2021

An investigative analysis in a subgroup of patients with R/R DLBCL from the SADAL study found increased OS associated with selinexor.

An investigative analysis in a...

12/02/2021

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology